Orphan Drugs Market (2032): Biologic Drugs, Oncology Therapies & Rare Disease Treatment Growth in United States Expansion

DataM Intelligence has released a new research report titled "Orphan Drugs Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the rare-disease treatment landscape. Designed to provide a clear and comprehensive perspective, the report covers the current market size, emerging opportunities, competitive developments, and the overall outlook of the global Orphan Drugs market.

Download Sample Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/orphan-drugs-market?sindhuri

Strategic Insights
• The global Orphan Drugs Market reached US$ 223.76 billion in 2023 and is projected to reach US$ 486.51 billion by 2032, growing at a CAGR of 9.1% during 2024-2032, driven by increasing rare-disease drug development, orphan drug designations, and supportive regulatory incentives.
• Rising investment in novel therapies and accelerated regulatory pathways is strengthening the orphan drug pipeline, with regulators providing incentives such as tax credits, market exclusivity, and expedited approvals to encourage pharmaceutical innovation for diseases with high unmet medical needs.
• Oncology remains the leading therapy area, supported by substantial unmet needs in rare cancers. The five leading oncology orphan drugs listed by DataM Intelligence generated nearly US$24.2 billion in sales in 2023, highlighting the commercial importance of rare-cancer therapies.
• North America continues to dominate the global orphan drugs market, supported by advanced healthcare infrastructure, strong pharmaceutical presence, government incentives, and the U.S. FDA's orphan drug framework, which can provide qualifying products with seven years of market exclusivity after approval.
• Biologic drugs, including gene therapies and monoclonal antibodies, are creating new opportunities for treating complex rare diseases, while emerging players and innovative biotech companies continue to expand the development pipeline.
• Key industry players include Johnson & Johnson, AbbVie, Vertex Pharmaceuticals, AstraZeneca, Incyte, Biogen, Novartis, Roche, Pfizer, and Bristol-Myers Squibb, alongside emerging companies such as Can-Fite, Mustang Bio, Kind Pharmaceuticals, Cabaletta Bio, and Ionis Pharmaceuticals.

United States: Recent Industry Developments
✅ August 2026: Regeneron Pharmaceuticals received U.S. FDA approval for garetosmab (Pasatru), a novel treatment for fibrodysplasia ossificans progressiva (FOP), highlighting continued innovation in ultra-rare disease therapies.
✅ August 2026: Ultragenyx Pharmaceutical received the first U.S. FDA approval for Genglycos, a gene therapy for glycogen storage disease type Ia (GSDIa), strengthening the role of advanced genetic medicines in the orphan-drug pipeline.
✅ July 2026: The U.S. FDA approved Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary immunoglobulin A nephropathy, adding another rare-disease therapy to the U.S. treatment landscape.
✅ March 2026: The FDA approved Avlayah (tividenofusp alfa-eknm) for neurological manifestations of Hunter syndrome, demonstrating continued regulatory momentum for treatments targeting rare genetic disorders.

List of Key Players 2026:
Johnson & Johnson Services, Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, AstraZeneca, Inc., Biogen Inc. and Novartis AG.

Company Evaluation
Leading pharmaceutical companies such as Johnson & Johnson, AbbVie and Novartis are strengthening their orphan-drug portfolios through established rare-disease therapies, strong commercial capabilities and expanding development pipelines. Johnson & Johnson is particularly well positioned in the orphan-drug space, supported by strong sales from rare-disease and oncology products.

Innovative companies such as Vertex Pharmaceuticals and Biogen are advancing specialized therapies for rare diseases, while emerging players including Ionis Pharmaceuticals, Can-Fite BioPharma and Cabaletta Bio are developing novel approaches targeting high-unmet-need conditions.

Growth Forecast Projected 2026:
The Global Orphan Drugs Market is anticipated to grow at a considerable rate during the forecast period between 2024 and 2032. The market reached approximately US$223.76 billion in 2023 and is expected to reach US$486.51 billion by 2032, expanding at a CAGR of 9.1%. Rising orphan-drug designations, increasing novel drug development, regulatory incentives and growing demand for therapies targeting rare diseases are expected to support market expansion throughout the forecast period.

In 2026, the orphan-drug landscape continues to benefit from strong rare-disease pipelines and supportive regulatory developments, although high treatment costs and pricing/access challenges remain important factors influencing market adoption.

Get a Customized Industry Report:
https://www.datamintelligence.com/customize/orphan-drugs-market?sindhuri

Key Developments 2025-2026:
✅ August 2026: The U.S. FDA approved Regeneron's Pasatru (garetosmab) for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder, marking another major advancement in targeted therapies for ultra-rare diseases.
✅ July 2026: The U.S. FDA approved Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary immunoglobulin A nephropathy, adding another rare-disease treatment to the growing U.S. therapeutic landscape.
✅ May 2026: The FDA approved Bizengri (zenocutuzumab-zbco) for adults with advanced or metastatic cholangiocarcinoma carrying an NRG1 gene fusion, highlighting continued development of precision therapies for rare cancers.

✅ March 2026: The FDA expanded the rare-disease treatment landscape with approvals including Avlayah for neurological manifestations of Hunter syndrome, Wellcovorin for cerebral folate transport deficiency, and Yuviwel for pediatric patients with achondroplasia.
✅ January 2026: The FDA approved Zycubo (copper histidinate) as the first treatment for children with Menkes disease, addressing a significant unmet need in this rare genetic disorder.
✅ December 2025: The FDA approved Waskyra, the first cell-based gene therapy for Wiskott-Aldrich syndrome, demonstrating the growing role of gene and cell therapies in rare-disease drug development.
✅ September 2025: The FDA introduced Rare Disease Evidence Principles (RDEP) to provide clearer and more predictable evidence expectations for therapies targeting rare diseases with very small patient populations and significant unmet medical needs.

How Our Market Research Process Works:
The global Orphan Drugs Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates key market-influencing factors, including rare-disease prevalence, orphan drug designations, regulatory incentives, clinical development activity, pricing and reimbursement trends, competitive intensity, and healthcare policy developments. It also analyzes advancements in biologics, gene therapies, monoclonal antibodies, precision medicine, and other innovative treatment approaches.

In addition, the report assesses emerging drug pipelines, clinical trial activity, regulatory approvals, market access strategies, investment opportunities, and developments across major therapeutic areas such as oncology, hematology, central nervous system disorders, cardiovascular diseases, endocrine disorders, respiratory diseases, and immunologic conditions. The research further evaluates regional market dynamics, competitive strategies, pricing pressures, unmet medical needs, and potential barriers that could influence the future expansion of the global orphan drugs ecosystem.

Recent Mergers & Acquisitions (M&A) 2025-2026:
• February 2025: Pharming Group acquired a controlling stake in Abliva AB, a Swedish biotechnology company developing therapies for mitochondrial diseases, strengthening Pharming's rare-disease pipeline. Pharming subsequently obtained full ownership in June 2025.

• May 2026: Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals for approximately US$4.1 billion, expanding its presence in the U.S. and strengthening its focus on brain health and rare diseases. The transaction is expected to close in the third quarter of 2026.
• July 2026: Warburg Pincus was reported to be nearing an acquisition of PANTHERx Rare, a specialty pharmacy focused on rare and orphan diseases, in a deal reportedly valued at more than US$7 billion including debt, highlighting growing private-equity interest in rare-disease healthcare.
• August 2026: PTC Therapeutics was selected as the winning bidder to acquire ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics for US$111 million upfront, plus up to US$100 million in contingent milestones.

Japan: Recent Industry Developments
✅ June 2026: Nippon Shinyaku received Orphan Drug Designation from Japan's MHLW for NS-035 for the treatment of Fukuyama congenital muscular dystrophy, a rare genetic disorder particularly prevalent in Japan.
✅ June 2026: Quoin Pharmaceuticals received Japan's MHLW Orphan Drug Designation for QRX003, a topical therapy candidate for Netherton Syndrome. The designation provides development and regulatory incentives, including the potential for up to 10 years of market exclusivity upon approval.
✅ March 2026: Sanofi received Japan's MHLW Orphan Drug Designation for rilzabrutinib for IgG4-related disease, supporting development of a novel oral BTK inhibitor for this rare immune-mediated disorder.
✅ September 2025: Nippon Shinyaku received Orphan Drug Designation in Japan for buloxibutid (NS-421/C21) for idiopathic pulmonary fibrosis. The candidate was licensed from Vicore Pharma for development and commercialization in Japan.
✅ September 2025: Dyne Therapeutics received Japan's MHLW Orphan Drug Designation for DYNE-251, an investigational therapy for Duchenne muscular dystrophy, supporting its development under the Japanese rare-disease regulatory pathway.
✅ January 2025: KalVista Pharmaceuticals received Japan's Orphan Drug Designation for sebetralstat and submitted an NDA for hereditary angioedema, advancing its plans to potentially introduce an oral on-demand treatment for HAE in Japan.

Unlock & Gain Complete 360° Market Visibility:
https://www.datamintelligence.com/buy-now-page?report=orphan-drugs-market?sindhuri

Segments Covered in the Global Orphan Drugs Market:
By Product Type
The market is segmented into small molecules (45%), biologic drugs (50%), and others (5%). Biologic drugs dominate the market, with gene therapies (15%), monoclonal antibodies (25%), and other biologic drugs (10%) collectively accounting for the largest share, driven by advancements in precision medicine, targeted therapies, and innovative treatments for rare diseases. Small molecules also represent a significant share due to their established use, oral administration advantages, and broad application across multiple rare disease indications. Gene therapies are witnessing strong growth as advances in genetic medicine enable potentially long-lasting or curative treatments for inherited rare disorders, while monoclonal antibodies continue to gain traction in oncology, immunology, and hematological conditions. Others include emerging therapeutic approaches and specialized orphan drug products serving niche patient populations.

By Therapy Area
The market is divided into oncology (38%), hematology diseases (15%), central nervous system (12%), cardiovascular (5%), endocrine (5%), respiratory (4%), immunologic conditions (8%), gastro-intestinal (3%), musculoskeletal (3%), dermatology (3%), and others (4%). Oncology leads the segment due to the high prevalence of rare cancers, increasing development of targeted orphan therapies, and growing investment in precision oncology. Hematology diseases and central nervous system disorders also account for substantial shares because of significant unmet medical needs and increasing approvals of specialized therapies for rare blood and neurological disorders. Immunologic conditions are expanding steadily with the development of biologics and targeted treatments, while endocrine, cardiovascular, respiratory, gastro-intestinal, musculoskeletal, and dermatological applications continue to grow as pharmaceutical companies expand their rare disease pipelines.

By Region
North America - 42% Share
North America leads the market due to strong orphan drug development activity, supportive regulatory incentives, substantial pharmaceutical R&D investments, and high adoption of innovative therapies for rare diseases across the United States and Canada.

Europe - 25% Share
Europe represents a significant share of the market, supported by established rare disease policies, regulatory incentives for orphan medicinal products, growing investments in advanced therapies, and increasing access to innovative treatments across countries such as Germany, France, the UK, Italy, and Spain.

Asia-Pacific - 20% Share
Asia-Pacific is expanding rapidly due to improving healthcare infrastructure, increasing awareness of rare diseases, growing pharmaceutical research capabilities, and rising investments in biologics and advanced therapies across China, Japan, South Korea, India, and other emerging markets.

People Also Ask:
1. What are the major product types in the orphan drugs market?
A: The market is segmented into small molecules, biologic drugs, and other product types. Biologic drugs include gene therapies, monoclonal antibodies, and other biologic therapies.

2. Which therapy areas are covered in the orphan drugs market?
A: The market covers oncology, hematology diseases, central nervous system disorders, cardiovascular diseases, endocrine disorders, respiratory diseases, immunologic conditions, gastrointestinal diseases, musculoskeletal disorders, dermatology, and others.

3. How do regulatory incentives support the orphan drugs market?
A: Regulatory authorities provide incentives such as orphan drug designation, tax credits, expedited approval pathways, and market exclusivity to encourage pharmaceutical companies to develop treatments for rare diseases. In the U.S., qualifying orphan products can receive seven years of market exclusivity after approval.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.